Alexander Liede
Overview
Explore the profile of Alexander Liede including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Birck M, Ferreira R, Curi M, Krueger W, Julian G, Liede A
Sci Rep
. 2023 Oct;
13(1):17739.
PMID: 37853013
Our study assessed DATASUS as a potential source for pharmacoepidemiologic studies in rheumatoid arthritis (RA) in the Brazilian population focusing on treatment patterns and determinants of initiating or switching to...
2.
Liede A, Sebby W, Miriyala A, Potluri R, Mazumder D, Ghosh A, et al.
BMC Cancer
. 2023 Jan;
23(1):78.
PMID: 36690978
Background: Incidence and risk factors for seizures among women with advanced breast cancer (BC) and brain metastases are not well characterized across treatment-related or clinical subtypes. This study leveraged a...
3.
Jin Y, Landon J, Krueger W, Liede A, Desai R, Kim S
BioDrugs
. 2022 Jun;
36(4):521-535.
PMID: 35771381
Background: Previous observational studies utilizing administrative claims data have largely been unable to consider clinical factors that may be related to patterns of drug use among patients with rheumatoid arthritis...
4.
Tyczynski J, Potluri R, Kilpatrick R, Mazumder D, Ghosh A, Liede A
Oncol Ther
. 2021 Apr;
9(2):471-488.
PMID: 33909273
Introduction: The incidence of pneumonitis, a treatment-related adverse event (AE) in non-small cell lung cancer (NSCLC) patients, has been studied in the United States mostly through clinical trials and retrospective...
5.
Mansfield C, Metcalfe K, Snyder C, Lindeman G, Posner J, Friedman S, et al.
Hered Cancer Clin Pract
. 2020 Oct;
18:20.
PMID: 33014209
Background: Women with a or mutation have high lifetime risks of developing breast and ovarian cancer. The decision to embark on risk reduction strategies is a difficult and personal one....
6.
Metcalfe K, Price M, Mansfield C, Hallett D, Lindeman G, Fairchild A, et al.
Br J Cancer
. 2020 May;
123(2):268-274.
PMID: 32393849
Background: Women with a BRCA1 or BRCA2 mutation have high lifetime risks of developing breast and ovarian cancers. We sought to estimate the prevalence of cancer-related distress and to identify...
7.
McGrath L, Hernandez R, Overman R, Reams D, Liede A, Brookhart M, et al.
Cancer Med
. 2018 Dec;
8(1):374-382.
PMID: 30537194
Background: Prior to 2018, intravenous bisphosphonates (IV BPs) were the only therapies recommended to prevent skeletal-related events for patients diagnosed with multiple myeloma (MM). We examined patterns of IV BP...
8.
Mues K, Bogdanov A, Monda K, Yedigarova L, Liede A, Kallenbach L
Clin Epidemiol
. 2018 Dec;
10:1667-1677.
PMID: 30532597
Background: Familial hypercholesterolemia (FH) is a condition characterized by high cholesterol levels and increased risk for coronary heart disease (CHD) that often goes undiagnosed. The Dutch Lipid Network Criteria (DLNC)...
9.
Liede A, Hernandez R, Wade S, Bo R, Nussbaum N, Ahern E, et al.
Oncoimmunology
. 2018 Dec;
7(12):e1480301.
PMID: 30524886
After a case report of profound clinical response in a melanoma patient following treatment with an immune checkpoint inhibitor (ICI) and RANK-ligand inhibitor denosumab, we identified similar patients from electronic...
10.
McGrath L, Overman R, Reams D, Cetin K, Liede A, Narod S, et al.
Clin Epidemiol
. 2018 Oct;
10:1349-1358.
PMID: 30288124
Purpose: Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the...